Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on February 18, 2022. The report addresses a corporate governance amendment regarding the company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a by-law amendment and does not contain financial performance data.
Material Changes
The primary material change reported is an amendment to the company's by-laws:
- Board Size Reduction: The Board of Directors amended Article III, Section 2 of the by-laws to reduce the number of directors from thirteen to twelve.
- Effective Date: This change is effective as of April 29, 2022.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the procedural update of the by-laws.
Investor Verification Checklist
- Verify the effective date of the board size reduction (April 29, 2022).
- Confirm the new total number of directors (12) versus the previous count (13).
- Review the attached Exhibit 3.1 for the full text of the amended and restated By-Laws.